Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Appili Therapeutics Inc T.APLI

Alternate Symbol(s):  APLIF

Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Company’s anti-infective product development portfolio includes three programs, including ATI-1701, ATI-1801 and ATI-1501. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of thousands of people around the world annually. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole.


TSX:APLI - Post by User

Post by ecanadian2on Mar 16, 2022 12:37am
151 Views
Post# 34517394

Will Lind be converting $3 mil into shares after Mar 18?!!

Will Lind be converting $3 mil into shares after Mar 18?!!Will Lind be converting $3 million into shares after Friday March 18?! That would be 10s of millions of shares unloaded on the illiquid APLI market. Scary ... still no update from APLI on this.

"Under the previously disclosed Funding Agreement, Appili issued to Lind a secured convertible security with a face value of $4.095 million and a 24-month maturity date. Under the revised terms, Appili has agreed to make a voluntary prepayment of $1 million towards the principal amount outstanding under the Funding Agreement. In exchange, Lind has agreed to a standstill period expiring on March 18, 2022 during which Lind shall not be entitled to convert any of the remaining principal amount outstanding into Appili shares, which is now approximately $3 million."
<< Previous
Bullboard Posts
Next >>